

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Bohuon Olivier</u> (Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u> (Street) <u>ABBOTT PARK</u> <u>IL</u> <u>60064-6400</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/24/2006</u>	3. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES [ABT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <div>Director 10% Owner</div> <div><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)</div> <div><u>Senior Vice President</u></div>	
		5. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line) <div><input checked="" type="checkbox"/> Form filed by One Reporting Person</div> <div>Form filed by More than One Reporting Person</div>	

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common shares without par value</u>	<u>20,830</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Option (right to buy)⁽¹⁾</u>	<u>06/01/2005</u>	<u>05/31/2013</u>	<u>Common shares</u>	<u>35,468</u>	<u>41.7836</u>	<u>D</u>	
<u>Option (right to buy)⁽¹⁾</u>	<u>06/01/2006</u>	<u>05/31/2013</u>	<u>Common shares</u>	<u>17,734</u>	<u>41.7836</u>	<u>D</u>	
<u>Option (right to buy)⁽¹⁾</u>	<u>02/20/2004</u>	<u>02/19/2014</u>	<u>Common shares</u>	<u>21,281</u>	<u>41.0317</u>	<u>D</u>	
<u>Option (right to buy)⁽¹⁾</u>	<u>02/20/2007</u>	<u>02/19/2014</u>	<u>Common shares</u>	<u>10,639</u>	<u>41.0317</u>	<u>D</u>	
<u>Option (right to buy)⁽²⁾</u>	<u>02/18/2006</u>	<u>02/17/2015</u>	<u>Common shares</u>	<u>11,600</u>	<u>46.34</u>	<u>D</u>	
<u>Option (right to buy)⁽²⁾</u>	<u>02/18/2007</u>	<u>02/17/2015</u>	<u>Common shares</u>	<u>11,600</u>	<u>46.34</u>	<u>D</u>	
<u>Option (right to buy)⁽²⁾</u>	<u>02/18/2008</u>	<u>02/17/2015</u>	<u>Common shares</u>	<u>11,600</u>	<u>46.34</u>	<u>D</u>	
<u>Option (right to buy)⁽²⁾</u>	<u>02/17/2007</u>	<u>02/16/2016</u>	<u>Common shares</u>	<u>12,000</u>	<u>44.16</u>	<u>D</u>	
<u>Option (right to buy)⁽²⁾</u>	<u>02/17/2008</u>	<u>02/16/2016</u>	<u>Common shares</u>	<u>12,000</u>	<u>44.16</u>	<u>D</u>	
<u>Option (right to buy)⁽²⁾</u>	<u>02/17/2009</u>	<u>02/16/2016</u>	<u>Common shares</u>	<u>12,000</u>	<u>44.16</u>	<u>D</u>	

Explanation of Responses:

1. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3.
2. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.

John A. Berry, by power of attorney for Olivier Bohuon
** Signature of Reporting Person

05/01/2006
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.